Trials / Completed
CompletedNCT02675478
Phase 1 Study of Quizartinib
A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC220 |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2018-11-13
- Completion
- 2018-11-13
- First posted
- 2016-02-05
- Last updated
- 2019-02-12
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02675478. Inclusion in this directory is not an endorsement.